NCT05099445

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 82 Years
• Healthy volunteers: Accepted

Summary

This is a multicenter, open-label parallel-group to evaluate single oral doses of INCB000928 in participants with varying level of renal function or impairment.

Conditions

• Renal Impairment
• Hemodialysis

Interventions

Type	Name	Description
DRUG	INCB000928	INCB000928 200 mg will be administered on Day 1 of each treatment period.

Timeline

• Start date: 2021-12-14
• Primary completion: 2023-02-19
• Completion: 2023-02-27
• First posted: 2021-10-29
• Last updated: 2023-05-15

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study